Pipeline

Our Drug Candidates

UroGen is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC.  In addition, UroGen is developing two additional clinical-stage drug candidates, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer and BotuGel, for the treatment of overactive bladder and interstitial cystitis.

Pipeline_V003

MitoGel™

MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma (UTUC), an urothelial cancer in the upper tract. UroGen has received Orphan Drug Designations from the FDA for MitoGel for the treatment of UTUC.

VesiGel™ 

VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Vesimune™ 

Vesimune is a new formulation of the TLR7 agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ (CIS), a high-grade form of NMIBC. UroGen has received Orphan Drug Designation from the FDA for Vesimune for the treatment of CIS.

BotuGel™,

BotuGel is a novel intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC).  The Company recently licensed the BotuGel program to Allergan for further development.